The possibility of identifying CNVs, such as 1p/19q codeletion, for the diagnosis of glioma was proven only for the TruSight Tumor 170 panel (Na et al., 2019), which, however, lacks the important glioma diagnostic genes ATRX, CIC, FUBP1, and CDKN2B. EU market trades TruSight Oncology Comprehensive examining 517 genes under CE-IVD certificate (TruSight Oncology Comprehensive EU, 2023). The gene discussed is CDKN2B; the disease is glioma.